IceCure Medical (NASDAQ:ICCM) Stock Moved Up to “Hold” by Zacks Research

Zacks Research upgraded shares of IceCure Medical (NASDAQ:ICCM) from a strong sell rating to a hold rating in a research note issued to investors on Monday morning,Zacks reports.

A number of other analysts have also weighed in on ICCM. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th. Wall Street Zen cut shares of IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.00.

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $1.10 on Monday. The company has a market cap of $3.77 million, a price-to-earnings ratio of -0.13 and a beta of 0.43. IceCure Medical has a one year low of $1.03 and a one year high of $26.97. The firm has a fifty day moving average price of $2.15 and a two-hundred day moving average price of $4.86.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. The business had revenue of $0.91 million for the quarter. Equities research analysts expect that IceCure Medical will post -4.61 EPS for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance.